Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

MALDI-TOF Mass Spectrometer

By Drug Discovery Trends Editor | June 16, 2009

BrukerBruker Daltonics launched its next-generation ultrafleXtreme MALDI-TOF/TOF mass spectrometer, the only instrument combining true 1 kHz speed in both TOF and TOF/TOF modes with ultra-high performance and extreme flexibility for a broad variety of complementary research, clinical and applied proteomics applications. In proteomics, MALDI-TOF/TOF is highly complementary to ESI-MS/MS with Bruker’s latest high-capacity ion traps with ETD, and to ultra-high resolution (UHR) ESI-Q-q-TOF maXis systems, as both MALDI and ESI are required for highest coverage and flexibility in modern protein analysis.


The new ultrafleXtreme incorporates key inventions, Bruker’s proprietary smartbeam-II laser technology at 1 kHz, and the latest ion optics innovations. It is the only MALDI-TOF/TOF instrument that truly enables high-throughput 1 kHz biomarker discovery and quantitation, as well as fast, high-performance tissue molecular imaging with a laser spot size close to single cell spatial resolution. LC-MALDI can be performed with unmatched mass resolution, mass accuracy and data acquisition speed. Bruker’s unique Edmass protein sequencing capabilities allow very rapid and sensitive intact protein characterization and sequencing with read lengths up to and beyond 80 residues, and with direct analysis of N- and C- terminal modifications.


The full 1 kHz smartbeam-II laser enables ultra-high data acquisition speed in both MS and MS/MS at full systems performance. The proprietary smartbeam laser provides unprecedented analytical and matrix flexibility in workflows from protein tissue imaging, intact proteins analysis, biologics, or oligo QC, to LC-MALDI proteomics – all fully enabled at 1-1000 Hz repetition rates. Broadband mass resolving power up to 40,000 enables precision proteomics via Bruker’s PAN technology for highest mass resolution across a very broad mass range, not just at a selected optimum.


The novel FlashDetector combined with a new 4 GHz digitizer and latest advances in electronics provide unmatched mass resolving power up to 40,000 and 1 ppm mass accuracy.


Bruker’s patented smartbeam technology is already widely accepted in the industry. The ultrafleXtreme now enables laser focus diameters down to 10 µm for high spatial resolution imaging without pixel overlap. Importantly, spectral quality and signal intensity are maintained at even the smallest laser beam diameters.


The laser-irradiation self-cleaning MALDI Perpetual Ion Source ensures long-term high-performance operation. Very long MALDI laser lifetime in combination with automated source cleaning in just minutes leads to high uptime and low maintenance costs.


Data retrieval and interpretation is provided by fully integrated software platforms designed, progressed, and supported by Bruker with leading proteomics experts.


ProteinScape 2.0 ensures confident information from quantitative studies using either label-free or ICPL-4plex, SILAC, iTRAQ-8plex or user-defined label technologies, integrates multiple datasets across large proteomic studies and generates reports in accordance to standard publication guidelines.


The BioTools 3.2 bioinformatics platform is now extended to top-down protein sequencing for recombinant protein work, e.g. in biotherapeutics and biosimilars characterization and QC.


flexImaging 2.1 is the standard in biomarker discovery based on MALDI tissue molecular imaging and is fully compatible with clinical histology.


Bruker Daltonics


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE